The strategy aims to end the global TB epidemic, with targets to reduce TB deaths by 95% and to cut new cases by 90% between 2015 and 2035.

Phumeza Tisile, co-author of the DR-TB Manifesto and XDR-TB survivor, delivers urgent plea to World Health Assembly delegates on behalf of 50,000 supporters worldwide.

Breakthrough new medicines for drug-resistant TB to be made available for low- and middle-income countries as part of $160 million of new grants funded by UNITAID.

A study estimates that 999 792 children developed TB in 2010, of whom 31 948 had MDR-TB. This value is nearly double the 530 000 paediatric cases estimated by WHO to have occurred in 2012.

Deltyba has been granted a marketing authorization for use as part of an appropriate combination regimen for MDR-TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

New WHO report provides the most comprehensive picture of antibiotic resistance to date, with data from 114 countries, including information on resistance to medicines for treating HIV, malaria and tuberculosis.

Siyabulela Qwaka is the latest patient cured of drug resistant TB in MSF’s project in Khayelitsha, South Africa. His story is an inspiration for the others currently fighting the new form of tuberculosis against which existing drugs are of limited effectiveness.

STAND trial will test the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB.

Mounting problems with accessing life-saving products to diagnose and treat TB threaten the progress made against this communicable disease.

Released at a March regional meeting on tuberculosis in southern Africa's mines, these documents cover TB treatment harmonization, compensation and the economic benefits of regular TB screening of mining communities.